Loading clinical trials...
Loading clinical trials...
The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC)...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
Collaborators
NCT07607769 · Hepatocellular Carcinoma
NCT07610551 · HCC - Hepatocellular Carcinoma
NCT07012798 · Hepatocellular Carcinoma (HCC)
NCT07322848 · Hepatocellular Carcinoma (HCC), TACE, and more
NCT07478302 · Advanced Unresectable Hepatocellular Carcinoma
Local Institution - 0008
Los Angeles, California
Local Institution - 0048
Washington D.C., District of Columbia
Local Institution - 0053
Pensacola, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions